However, responses to BV were also apparent in T cell lymphomas that had low or absent CD30 expression, suggesting that the drug may also be dispersed to the tumor microenvironment and later released into the tumor cells as a bystander effect (35, 36). The gene discussed is TNFRSF8; the disease is T-cell non-Hodgkin lymphoma.